Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis secured exclusive worldwide rights to Abogen Biosciences' ABO2203 in a transaction worth up to $7.8 billion, consisting of $575 million upfront and up to $7.2 billion in milestone payments. The asset is an mRNA-encoded CD19xCD3 T-cell engager designed to tackle B-cell-driven autoimmune diseases by instructing a patient's own cells to manufacture the medicine inside the body. This acquisition represents a major push into in vivo RNA therapeutics following Abogen's prior commercial setback with a COVID-19 vaccine candidate.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novartis acquired exclusive worldwide rights to ABO2203 from Abogen Biosciences for $575 million upfront and up to $7.2 billion in milestone payments.
- ✓ ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases.
What changed
Abogen Biosciences agreed to license its mRNA-encoded CD19xCD3 T-cell engager ABO2203 to Novartis for $575 million upfront and up to $7.2 billion in milestones.
Live updates
-
Novartis Acquires Abogen's ABO2203 in $7.8B Autoimmune Deal
Novartis secured exclusive worldwide rights to Abogen Biosciences' ABO2203 in a transaction worth up to $7.8 billion, consisting of $575 million upfront and up to $7.2 billion in milestone payments. The asset is an mRNA-encoded CD19xCD3 T-cell engager designed to tackle B-cell-driven autoimmune diseases by instructing a patient's own cells to manufacture the medicine inside the body. This acquisition represents a major push into in vivo RNA therapeutics following Abogen's prior commercial setback with a COVID-19 vaccine candidate.
Why it matters
The transaction stands out as a high-value bet on in vivo protein production using messenger RNA technology outside the traditional infectious disease space. Licensing agreements and M&A activity across the sector highlight heavy industry investment in alternative therapeutic technologies, though October deal values peaked at $2 billion for separate acquisitions. Abogen pivots toward autoimmune applications after failing to commercialize its earlier COVID-19 vaccine.
What is confirmed
- Novartis acquired exclusive worldwide rights to ABO2203 from Abogen Biosciences for $575 million upfront and up to $7.2 billion in milestone payments.
- ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases.
What to watch next
- Clinical trial initiations and regulatory filings for ABO2203
- Progress on milestone payments tied to the development of the in vivo RNA therapy
confidence 100%Sources used for this update (3)
- www.fiercebiotech.com — Biotech | Fierce Biotech
- www.originbrief.app — Pharma & Biotech Monthly Report · News & Updates · November 1 ...
- www.labiotech.eu — Top biotech deals in October 2026
-
Novartis inks $7.8B deal with Abogen for in vivo autoimmune T-cell engager
Novartis has secured exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager developed by Abogen Biosciences, for $575 million upfront and up to $7.2 billion in milestone payments. The therapy targets B-cell-driven autoimmune diseases by using patients' own cells to produce the medicine in vivo. This deal marks a significant investment in in vivo RNA technology and follows Abogen's commercial failure with a prior COVID-19 vaccine candidate.
Why it matters
The agreement highlights Novartis' commitment to expanding its portfolio in autoimmune diseases and mRNA technology. Abogen Biosciences, a Suzhou-based company, has been working on innovative treatments using mRNA-encoded therapies. The deal's substantial milestone payments reflect the potential of ABO2203 in addressing unmet medical needs in autoimmune diseases.
What is confirmed
- Novartis secured exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager developed by Abogen Biosciences.
- The deal includes an upfront payment of $575 million and potential milestone payments reaching approximately $7.2 billion.
- ABO2203 treats B-cell-driven autoimmune diseases by using the patient's own cells to produce the medicine in vivo.
What to watch next
- Progress in clinical trials for ABO2203
- Novartis' plans for commercialization and marketing of ABO2203
- Regulatory approvals for the deal
confidence 100%Sources used for this update (11)
- www.distillintelligence.com — Latest Novartis News & Announcements | Distill
- www.yeasenbio.com — From Molecule to Platform: What the Abogen–Novartis Deal ...
- www.bioxconomy.com — Partnering recent news | BioXconomy
- www.pornhub.com — Real Ip Cam Porn Videos | Pornhub.com
- www.eporner.com — Ip Porn - Ip Cam & Ip Cam Videos - EPORNER
- linsemao.com — IP Camera - Stingy cat - Linsemao
- area51.porn — Ip camera XXX video on Area51.porn
- pornzog.com — Ip Camera De - PornZog Free Porn Clips
- www.erome.com — Ip Camera - Porn Photos & Videos - EroMe
- tube4world.com — Ip cam - video / Latest - Tube For World
- www.eporner.com — Ip Cam Porn - Cam Girl & Indian Cam Videos - EPORNER
-
Novartis acquires rights to Abogen mRNA therapy in $7.8 billion deal
Novartis has secured exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager developed by Suzhou-based Abogen Biosciences. The deal includes an upfront payment of $575 million and potential milestone payments reaching approximately $7.2 billion. The therapy treats B-cell-driven autoimmune diseases by using the patient's own cells to produce the medicine in vivo. This agreement follows a commercial failure of Abogen's prior COVID-19 vaccine candidate and marks a major investment in in vivo RNA technology.
Why it matters
Abogen Biosciences was founded in 2019. The deal occurs as Chinese biotech firms reach a record $139.4 billion in overseas licensing deals for 2026.
What is confirmed
- Novartis paid $575 million upfront for exclusive worldwide rights to ABO2203.
- Potential milestone payments for the ABO2203 agreement total approximately $7.2 billion.
- Abogen Biosciences is a mRNA biotech company founded in 2019 and based in Suzhou.
- ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager.
Still unconfirmed
- Chinese biotech firms hit $139.4B in overseas licensing deals in 2026.
What to watch next
- Clinical trial results for ABO2203 in autoimmune disease patients
- Regulatory filings for the mRNA-encoded therapy
- Further licensing deals from Abogen Biosciences
confidence 90%Sources used for this update (3)
- www.biobucks.co — Biotech BD&L Tracker 2026: 156 Licensing & Partnering Deals
- www.thepharmaletter.com — Abogen Biosciences | The Pharma Letter | The Pharmaletter
- www.nextmsc.com — China Biotech Licensing Deals:Update 2026 - nextmsc.com
-
Novartis acquires global rights to Abogen mRNA therapy in $7.8 billion deal
Novartis has secured exclusive worldwide rights to ABO2203, an experimental mRNA-encoded CD19xCD3 T-cell engager from Abogen Biosciences. The agreement includes an upfront payment of $575 million and total potential payments reaching $7.8 billion. The therapy targets B-cell-driven autoimmune diseases by programming the patient's own cells to manufacture the medicine. This acquisition represents a significant investment in in vivo RNA technology and a strategic pivot for Abogen following the commercial failure of its previous COVID-19 vaccine candidate.
Why it matters
The deal tests whether the human body can be used as a production facility for complex medicines. It occurs amid shifting geopolitical tensions regarding biotechnology collaborations between the West and China.
What is confirmed
- Novartis paid $575 million upfront for access to Abogen's RNA technology.
- The total value of the transaction is up to $7.8 billion.
- The licensed asset ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager for B-cell-driven autoimmune diseases.
Still unconfirmed
- The US government is considering allowing pharmaceutical deals between the US and China to continue while remaining cautious in other sectors.
What to watch next
- Clinical trial results for ABO2203
- Official US government policy updates on US-China biotech investments
confidence 90%Sources used for this update (5)
- www.iam-media.com — Novartis inks $7.8 billion mRNA deal with Chinese company Abogen
- www.biospace.com — China - BioSpace
- www.newsnow.co.uk — Pharmaceuticals News | Latest Pharma News - NewsNow » Novartis
- biotechmorning.com — Novartis Just Bet $7.8 Billion That Your Body Can Build Its ...
- www.biospace.com — Autoimmune disease - BioSpace
-
Novartis Commits $7.8B to Abogen for mRNA Autoimmune Drug
Swiss pharmaceutical company Novartis has agreed to pay $575 million upfront in a transaction valued at up to $7.8 billion to secure global rights to Abogen Biosciences' experimental mRNA therapy ABO2203. The licensed drug is an mRNA-encoded CD19xCD3 T-cell engager designed to treat B-cell-driven autoimmune diseases by turning the patient's body into a manufacturing facility. This transaction grants Novartis exclusive worldwide rights to the asset and marks a major test for Abogen's technology following the commercial miss of its earlier COVID-19 vaccine.
Why it matters
Abogen Biosciences previously focused on developing a COVID-19 shot, but that product missed the commercial window, forcing the company to prove its mRNA technology held value beyond traditional vaccines. This new partnership provides validation for that broader therapeutic pipeline. The collaboration centers on an in vivo approach that aims to lower the risk of dangerous cytokine release.
What is confirmed
- Novartis has entered a licensing and option agreement with Chinese biotech Abogen Biosciences valued at up to $7.8 billion.
- Novartis is paying $575 million upfront for worldwide rights to the experimental autoimmune treatment ABO2203.
- The drug is an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases.
Still unconfirmed
- The deal was finalized weeks after trial failures erased $30 billion in value.
What to watch next
- Clinical trial progression and safety data for the ABO2203 therapy
- Novartis exercising options for additional RNA programs under the agreement
confidence 95%Sources used for this update (10)
- pharma.economictimes.indiatimes.com — Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
- www.bioreview.com — The Body as a Factory: Novartis's $7.8B Bet on mRNA T-Cell ...
- finance.yahoo.com — Novartis Strengthens RNA Therapeutics Pipeline With $7.8B ...
- lifescivoice.com — Abogen Lands $7.8B Novartis Deal for Autoimmune Therapy
- www.manufacturingchemist.com — Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T ...
- www.biospace.com — How Abogen went from COVID hype to a $7.8B Novartis deal
- www.europesays.com — Novartis signs $7.8B mRNA deal with Chinese biotech
- globalpolitics.info — Novartis Partners with Abogen on $7.8 Billion Biotech Deal
- www.biospace.com — Novartis - BioSpace
- for.you.com — Novartis Abogen Deal: $575M Upfront Bet on mRNA Autoimmune Drug
-
Novartis licenses Abogen mRNA therapy in deal worth up to $7.8 billion
Novartis has entered a licensing and option agreement with Chinese biotech Abogen Biosciences for an mRNA-encoded T cell engager. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront for global rights to the experimental autoimmune treatment. The therapy uses an in vivo approach to produce a CD3xCD19 T cell engager inside the body, which Abogen claims may lower the risk of dangerous cytokine release. The agreement also includes options for other potential RNA programs.
Why it matters
Western pharmaceutical firms are increasingly sourcing innovation from China to offset the impact of the upcoming patent cliff. This deal highlights a trend of large-scale tie-ups between global drug makers and Chinese startups.
What is confirmed
- Novartis signed a licensing deal with Abogen Biosciences worth up to $7.8 billion.
- Novartis will pay Abogen $575 million upfront for global rights to the experimental autoimmune treatment.
- The therapy is an mRNA-encoded T cell engager designed to produce a CD3xCD19 T cell engager inside the body.
- Abogen is a clinical-stage biotechnology group based in China.
Still unconfirmed
- The in vivo approach could reduce the likelihood of dangerous cytokine release.
What to watch next
- Clinical trial results for the CD3xCD19 T cell engager
- Novartis' decision to exercise options on additional RNA programs
confidence 100%Sources used for this update (10)
- WSJ — Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
- CNBC — Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
- fiercebiotech.com — Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
- axios.com — Novartis signs $7.8 billion drug deal with Chinese startup
- BioSpace — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
- www.cnbc.com — Novartis signs $7.8 billion Abogen biotech licensing deal - CNBC
- www.biospace.com — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen - BioSpace
- finance.yahoo.com — Novartis signs mRNA deal for about $7.8 billion with China's ...
- theclinicaltimes.com — Novartis signs Abogen deal worth up to $7.8 billion
- www.prnewswire.com — Abogen Announces Licensing and Option Agreement with Novartis ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community